Correlation
The correlation between VRNA and FINV is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
VRNA vs. FINV
Compare and contrast key facts about Verona Pharma plc (VRNA) and FinVolution Group (FINV).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: VRNA or FINV.
Performance
VRNA vs. FINV - Performance Comparison
Loading data...
Key characteristics
VRNA:
10.30
FINV:
1.98
VRNA:
6.33
FINV:
2.61
VRNA:
1.78
FINV:
1.34
VRNA:
9.87
FINV:
1.57
VRNA:
89.98
FINV:
7.59
VRNA:
6.15%
FINV:
10.79%
VRNA:
60.04%
FINV:
42.42%
VRNA:
-89.71%
FINV:
-89.64%
VRNA:
0.00%
FINV:
-19.07%
Fundamentals
VRNA:
$6.90B
FINV:
$2.21B
VRNA:
-$2.00
FINV:
$1.32
VRNA:
58.21
FINV:
0.16
VRNA:
30.49
FINV:
1.03
VRNA:
$118.54M
FINV:
$13.36B
VRNA:
$112.28M
FINV:
$10.72B
VRNA:
-$176.07M
FINV:
$4.86B
Returns By Period
In the year-to-date period, VRNA achieves a 74.85% return, which is significantly higher than FINV's 27.77% return.
VRNA
74.85%
12.37%
104.90%
572.74%
161.71%
76.36%
N/A
FINV
27.77%
4.63%
24.30%
81.50%
31.73%
46.99%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
VRNA vs. FINV — Risk-Adjusted Performance Rank
VRNA
FINV
VRNA vs. FINV - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Verona Pharma plc (VRNA) and FinVolution Group (FINV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
VRNA vs. FINV - Dividend Comparison
VRNA has not paid dividends to shareholders, while FINV's dividend yield for the trailing twelve months is around 3.31%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
VRNA Verona Pharma plc | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
FINV FinVolution Group | 3.31% | 3.49% | 4.39% | 4.13% | 3.45% | 4.49% | 7.17% |
Drawdowns
VRNA vs. FINV - Drawdown Comparison
The maximum VRNA drawdown since its inception was -89.71%, roughly equal to the maximum FINV drawdown of -89.64%. Use the drawdown chart below to compare losses from any high point for VRNA and FINV.
Loading data...
Volatility
VRNA vs. FINV - Volatility Comparison
Verona Pharma plc (VRNA) has a higher volatility of 13.72% compared to FinVolution Group (FINV) at 11.22%. This indicates that VRNA's price experiences larger fluctuations and is considered to be riskier than FINV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
VRNA vs. FINV - Financials Comparison
This section allows you to compare key financial metrics between Verona Pharma plc and FinVolution Group. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VRNA vs. FINV - Profitability Comparison
VRNA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Verona Pharma plc reported a gross profit of 72.85M and revenue of 76.26M. Therefore, the gross margin over that period was 95.5%.
FINV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, FinVolution Group reported a gross profit of 2.73B and revenue of 3.46B. Therefore, the gross margin over that period was 78.9%.
VRNA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Verona Pharma plc reported an operating income of -10.32M and revenue of 76.26M, resulting in an operating margin of -13.5%.
FINV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, FinVolution Group reported an operating income of 787.92M and revenue of 3.46B, resulting in an operating margin of 22.8%.
VRNA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Verona Pharma plc reported a net income of -16.32M and revenue of 76.26M, resulting in a net margin of -21.4%.
FINV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, FinVolution Group reported a net income of 680.71M and revenue of 3.46B, resulting in a net margin of 19.7%.